Immunocore (IMCR)
(Delayed Data from NSDQ)
$32.99 USD
+0.22 (0.67%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $33.05 +0.06 (0.18%) 7:58 PM ET
1-Strong Buy of 5 1
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IMCR 32.99 +0.22(0.67%)
Will IMCR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IMCR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMCR
CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down
FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales
IMCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises
UTHR Q2 Earnings Miss Estimates, Higher Tyvaso Sales Aid Revenues Y/Y
Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales
Other News for IMCR
Immunocore to report second quarter 2025 financial results and host call on August 7, 2025 | ...
Notable Two Hundred Day Moving Average Cross - IMCR
Tracking Baker Brothers Portfolio - Q1 2025 Update
Delcath Systems: Growing Fast, But Business Model Is Fragile
Immunocore Holdings (IMCR): HC Wainwright Maintains Buy Rating | IMCR Stock News